Bio-Rad Laboratories (BIO-N) Quote - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Day Low450.05

Day High460.90

Open:452.75

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Press & news

Latest News

Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer

Business Wire - Wed Mar 15, 6:58AM CDT

Business Wire

Wed Mar 15, 6:58AM CDT

Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences’ previous CEO, Jason Gammack, will be leaving...

Bio-Rad to Participate in Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference

Business Wire - Fri Feb 17, 8:00AM CST

Business Wire

Fri Feb 17, 8:00AM CST

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Citi’s 2023 Healthcare...

Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results

Business Wire - Thu Feb 16, 3:05PM CST

Business Wire

Thu Feb 16, 3:05PM CST

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022.

Latest Articles

Bio-Rad paying $55M to resolve US claims of failing to prevent foreign bribes, hiding payments

November 3, 2014

Virtek settles Bio-Rad claim

January 21, 2005

Profit optimism sends U.S. markets up

December 27, 2003

Mad-cow worries bite Wall Street

December 26, 2003

Mad-cow shock waves reverberate on markets

December 26, 2003

Virtek sells biotech instruments business

Patients pay the price in the genetic-testing battle

February 19, 2002

Gene test too expensive to use, U.S. labs say

February 7, 2002

Data Update

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.